Applying Risk-Adapted Approaches to Management of MDS

Access Activity

Overview / Abstract:

Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, medical oncologists, BMT specialists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with MDS.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Review validated MDS classification systems and risk-stratification models
Discuss the treatment algorithm for low-risk MDS considering patient eligibility for allogeneic stem-cell transplantation
Evaluate the latest data on novel approaches to the management of low- and high-risk MDS
Facilitate individual treatment-goal planning by reviewing clinical outcomes of novel agents in patient subgroups

Expiration

May 06, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5

Accreditation

ACCME, ACPE, ANCC

Presenters / Authors / Faculty

Mikkael A. Sekeres, MD, MS
Hetty Carraway, MD, MBA

Sponsors / Supporters / Grant Providers

Bristol Myers Squibb; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; and Taiho

Keywords / Search Terms

Relias LLC Relias, Free CME, MDS Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map